Chad Salisbury is Vice President, Manufacturing for Affinia Therapeutics. Affinia is a gene therapy company singularly focused on using innovations in gene therapy to lead the fight against devastating rare and prevalent diseases. He is accountable for oversight of all internal/external gene therapy manufacturing operations responsible for the timely delivery of quality product to meet clinical program timelines. Salisbury joined Affinia in October 2021 and his duties include building out Affinia's manufacturing supply network through CDMO partnerships to ensure robust, reliable supply chain for both clinical and commercial supply. His professional experience includes over twenty years of manufacturing, quality and supply chain experience across diverse biopharmaceutical industry platforms including gene therapies, vaccines, sterile injectables, small molecules, adjuvants and medical devices. Salisbury has worked for Eli Lilly, Novartis and Seqirus prior to joining Affinia. He received a Masters of business administration from Purdue University, a Masters of environmental management degree from Duke University and Bachelor degrees in mathematics and environmental studies from Alfred University.